DR. EDWARD H KOO, M.D.
Neurology at Gilman Dr, La Jolla, CA
License number
California G47266
Category
Medical Practice
Type
Neuropathology
License number
California G47266
Category
Neurology
Type
Neurology
Address
Address
9500 Gilman Dr, La Jolla, CA 92093
Phone
(858) 822-1024
(858) 822-1021 (Fax)
(858) 822-1021 (Fax)
Organization information
See more information about EDWARD H KOO at bizstanding.comEdward H Koo MD
8950 Villa Ln Jolla Dr #129, La Jolla, CA 92037
Categories:
Neurology Physicians & Surgeons
Phone:
(858) 622-5800 (Phone)
Professional information
Abeta42 Lowering Agents
US Patent:
2007025, Nov 1, 2007
Filed:
Apr 26, 2007
Appl. No.:
11/740800
Inventors:
Edward Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Sascha Weggen - Dusseldorf, DE
Todd Golde - Ponte Vedra Beach FL, US
Sascha Weggen - Dusseldorf, DE
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
A61K 38/00, G01N 1/00, G01N 33/53
US Classification:
424009100, 435007100, 435007210, 436501000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβlowering agent to a mammal under conditions in which levels of Aβare selectively reduced, levels of Aβare increased, and levels of Aβare unchanged. The invention provides methods and materials for developing and identifying Aβlowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβlowering agents and antioxidants, Aβlowering agents and non-selective secretase inhibitors, as well as Aβlowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβlowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβlowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Abeta 42 Lowering Agents
US Patent:
2002012, Sep 12, 2002
Filed:
Dec 7, 2001
Appl. No.:
10/012606
Inventors:
Edward Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
International Classification:
A61K031/195, A61K031/192
US Classification:
514/569000, 514/570000, 514/567000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Alowering agent to a mammal under conditions in which levels of Aare selectively reduced, levels of A8 are increased, and levels of Aare unchanged. The invention provides methods and materials for developing and identifying Alowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Alowering agents and antioxidants, Alowering agents and non-selective secretase inhibitors, as well as Alowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Alowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Alowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Abeta 42 Lowering Agents
US Patent:
2005008, Apr 28, 2005
Filed:
Aug 27, 2004
Appl. No.:
10/928925
Inventors:
Edward Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Todd Golde - Ponte Vedra Beach FL, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K038/00, C12Q001/37
US Classification:
435023000, 514002000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβlowering agent to a mammal under conditions in which levels of Aβare selectively reduced, levels of Aβare increased, and levels of Aβare unchanged. The invention provides methods and materials for developing and identifying Aβlowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβlowering agents and antioxidants, Aβlowering agents and non-selective secretase inhibitors, as well as Aβlowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβlowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβlowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Abeta42 Lowering Agents
US Patent:
2007025, Nov 1, 2007
Filed:
Apr 26, 2007
Appl. No.:
11/740791
Inventors:
Edward Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Sascha Weggen - Dusseldorf, DE
Todd Golde - Ponte Vedra Beach FL, US
Sascha Weggen - Dusseldorf, DE
Assignee:
Mayo Foundation for Medical Education - Rochester MN
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
A61K 49/00, A61P 25/28, G01N 33/53, G01N 33/566, G01N 33/567
US Classification:
424009100, 435007100, 435007210, 436501000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβlowering agent to a mammal under conditions in which levels of Aβare selectively reduced, levels of Aβare increased, and levels of Aβare unchanged. The invention provides methods and materials for developing and identifying Aβlowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβlowering agents and antioxidants, Aβlowering agents and non-selective secretase inhibitors, as well as Aβlowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβlowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβlowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Abeta42 Lowering Agents
US Patent:
2005018, Aug 25, 2005
Filed:
Apr 25, 2005
Appl. No.:
11/113789
Inventors:
Edward Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sacha Weggen - Mainz, DE
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sacha Weggen - Mainz, DE
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
The Regents of The University of California - Oakland CA
The Regents of The University of California - Oakland CA
International Classification:
C12Q001/68, C12Q001/00
US Classification:
435004000, 435006000, 436086000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβlowering agent to a mammal under conditions in which levels of Aβare selectively reduced, levels of Aβare increased, and levels of Aβare unchanged. The invention provides methods and materials for developing and identifying Aβlowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβlowering agents and antioxidants, Aβlowering agents and non-selective secretase inhibitors, as well as Aβlowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβlowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβlowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Edward H Koo, La Jolla CA
Specialties:
Neurologist
Address:
9500 Gilman Dr, La Jolla, CA 92093
Board certifications:
American Board of Pathology Sub-certificate in Neuropathology (Pathology), American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Edward Koo, San Diego CA
Work:
Va San Diego Healthcare System
3350 La Jolla Village Dr, San Diego, CA 92161 University of California at San Diego
9500 Gilman Dr, La Jolla, CA 92093 Perlman Medical Offices
9350 Campus Point Dr, La Jolla, CA 92037
3350 La Jolla Village Dr, San Diego, CA 92161 University of California at San Diego
9500 Gilman Dr, La Jolla, CA 92093 Perlman Medical Offices
9350 Campus Point Dr, La Jolla, CA 92037
Method Of Reducing Abeta42 And Treating Diseases
US Patent:
2008002, Jan 24, 2008
Filed:
Jun 21, 2007
Appl. No.:
11/766589
Inventors:
Edward Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sascha Weggen - Duesseldo, DE
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sascha Weggen - Duesseldo, DE
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
The Regents of The University of California - Oakland CA
The Regents of The University of California - Oakland CA
International Classification:
A61K 31/192, A61K 31/196, A61K 31/403, A61P 25/28
US Classification:
514411000, 514420000, 514567000, 514569000, 514570000, 514789000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβlowering agent to a mammal under conditions in which levels of Aβare selectively reduced, levels of Aβare increased, and levels of Aβare unchanged. The invention provides methods and materials for developing and identifying Aβlowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβlowering agents and antioxidants, Aβlowering agents and non-selective secretase inhibitors, as well as Aβlowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβlowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβlowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Method Of Reducing Abeta42 And Treating Diseases
US Patent:
2006000, Jan 5, 2006
Filed:
Jun 28, 2005
Appl. No.:
11/170776
Inventors:
Edward Mang Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sascha Weggen - Mainz, DE
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sascha Weggen - Mainz, DE
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
The Regents of The University of California - Oakland CA
The Regents of The University of California - Oakland CA
International Classification:
A61K 31/405, A61K 31/192, G01N 33/573
US Classification:
514420000, 514570000, 514569000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβlowering agent to a mammal under conditions in which levels of Aβare selectively reduced, levels of Aβare increased, and levels of Aβare unchanged. The invention provides methods and materials for developing and identifying Aβlowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβlowering agents and antioxidants, Aβlowering agents and non-selective secretase inhibitors, as well as Aβlowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβlowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβlowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Influence Of Lrp Cytoplasmic Domain On Abeta Production
US Patent:
2004003, Feb 26, 2004
Filed:
Jul 31, 2002
Appl. No.:
10/210175
Inventors:
Edward Koo - La Jolla CA, US
Claus Pietrzik - Nierstein, DE
Claus Pietrzik - Nierstein, DE
International Classification:
C07K014/705, C07H021/04, C12P021/02, C12N005/06
US Classification:
435/069100, 435/320100, 435/325000, 530/350000, 536/023500
Abstract:
A truncated dominant negative mammalian LDL receptor related protein (LRP) cytoplasmic tail mutant (LRP-CT) molecule and DNA sequences for its construction is described in this disclosure as is a method for disrupting generation of amyloid -protein (A). Methods for preventing or treating diseases wherein amyloid -protein (A) is a major constituent of amyloid plaques or amyloidosis by interfering with production of A are described, as is a high throughput assay for screening compounds that inhibit A production. Also described is a method for inhibiting LRP or APP:Fe65 interaction in vivo, and kit suitable for providing the required reactants for screening assays.